skip to main content

NSCLC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardLung CancerNSCLCSCE Medical Oncology

A patient with metastatic non-squamous NSCLC completes four cycles of carboplatin, pemetrexed and pembrolizumab with response and has preserved renal function and tolerable toxicity. Which continuation regimen reproduces the KEYNOTE-189 strategy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Pembrolizumab plus pemetrexed without carboplatin

KEYNOTE-189 stopped platinum after four induction cycles and continued pembrolizumab with pemetrexed. Continuing carboplatin adds cumulative toxicity outside the regimen; single-agent or intermittent-platinum alternatives do not reproduce the evidence-generating strategy, and observation omits active maintenance.

Reference: KEYNOTE-189 updated analysis. https://pubmed.ncbi.nlm.nih.gov/32150489/